Dr Brennan was previously President and CEO of Synlogic Inc, a clinical stage biotechnology company developing treatments for rare metabolic diseases based on synthetic biology. In that role, she led the organization from early-stage private company to a late-phase public company with internal GMP manufacturing capabilities, pioneering new regulatory pathways for bacterial therapeutics. She joined Synlogic as Chief Medical Officer in 2016 and was promoted to CEO in October 2018.

Prior to joining Synlogic, Aoife served as Vice President and Head of the Rare Disease Innovation Unit at Biogen where her responsibilities included the global marketing approvals of ALPROLIXTM, ELOCTATETM and SPINRAZATM as well as the advancement of several early-phase programs. She served as a Director of Ra Pharmaceuticals from Sept 2018 through their acquisition in April 2020 and currently serves as a Director of Fibrogen and Cerevance. Dr Brennan holds a medical degree from Trinity College Dublin, Ireland and is board certified in internal medicine as well as endocrinology and metabolism. She is a graduate of the Harvard Medical School Scholars in Clinical Science Program. Aoife is an advocate for early childhood education, a member of the MA Business Coalition for ECE and a member of the Board of Advisors of Lifescience Cares.

Earlier this year in Bruce Booth's blog From The Trenches Aoife Brennan spoke about her seven-year assignment at Synlogic Tx which ended earlier this year when an early readout of their Phase 3 program indicated that it was unlikely to meet its primary endpoint.

"The most unexpected lessons were the ones about teams and culture."

In this INSIGHTS Aoife will share her "case study" of building this biotech from scratch, initially also in the role of CMO, and then taking it public. She will share what lessons she learned about team building, trust, hiring, communications and why she made the U.S. TV show ‘The Bear’ required viewing for her entire team.